Skip to main content

Table. 3 First year and follow-up year treatment costs of each alternative (CDM inputs of treatment cost group setting; RMB)

From: Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China

Treatment

1st year

Subsequent years

Empagliflozin + SoC

9,682.79

10,057.76

Liraglutide + SoC

19,943.75

24,347.57

Sitagliptin + SoC

6,288.94

7,772.18

Basal bolus

19,866.77

19,866.77

  1. CDM IQVIA Core Diabetes Model, SoC standard of care
Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us